YM Biosciences and NRC Biotechnology Research Institute Produce New Breast Cancer Drug Candidates

14-Dec-2009 - YM BioSciences Inc. announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface ...

Small, beautiful and additive-free

Radically new microscope commercialized

17-Nov-2009 - The National Research Council Canada (NRC) recently helped Olympus to design and commercialize a CARS (Coherent Anti-stokes Raman Scattering) microscope. The new Olympus microscope is based on a femtosecond non-linear optical process called CARS, which stands for Coherent Anti-Stokes Raman ...

Med BioGene Receives Funding from National Research Council Canada to Develop Genetic Biomarkers for Cardiovascular Disease

12-Mar-2007 - Med BioGene Inc. announced that it has received a $307,000 contribution from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to develop genetic biomarkers for cardiovascular disease (CVD). "We believe that Med BioGene's expertise in gene expression and the ...

Amorfix receives support from Canadian government to accelerate development of blood test for Alzheimer's disease

21-Dec-2006 - Amorfix Life Sciences Ltd. announced that in addition to their own investment, the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) will share in the research and development of the company's proposed diagnostic test for Alzheimer's disease, EP-AD(tm), via a ...

MedMira's Biosensor Division to Collaborate with National Research Council on Breast Cancer Research

17-Nov-2006 - MedMira Inc. announced that it has entered into a collaborative agreement with the National Research Council of Canada (NRC), through its biosensor division, Maple BioSciences. The agreement will allow NRC to work with Maple BioSciences on the discovery and validation of breast cancer biomarkers. ...

Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study

11-Aug-2005 - Protox Therapeutics Inc. announced that it has signed an exclusive licence agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) and the University of Victoria (UVic) Innovation and Development Corporation (IDC). The licence grants Protox exclusive worldwide ...

Protox receives funding from NRC to develop lung cancer drug

09-Jun-2005 - Protox Therapeutics Inc. announced that it has received a financial contribution of up to $340,000 from the National Research Council ('NRC') Industrial Research Assistance Program ('IRAP'). The NRC has committed this money to the Company to support its development of Lung-H1, a therapeutic toxin ...

Helix identifies lead product candidate from DOS47 cancer therapeutic program

09-May-2005 - Helix BioPharma announced the selection of its lead product candidate derived from its novel DOS47 cancer therapeutic program. L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific antibody, to form a potential new drug product for the treatment of adenocarcinoma of ...